PrednisoneCastrationOrchiectomyTestosteroneVincristineAndrogensCyclophosphamideProstateDihydrotestosteroneGlucocorticoidsDoxorubicinProcarbazineAntineoplastic Combined Chemotherapy ProtocolsAndrogen AntagonistsSeminal VesiclesFlutamideMechlorethamineReceptors, AndrogenPrednisoloneAzathioprineAnxiety, CastrationImmunosuppressive AgentsTreatment OutcomeMelphalanClonixinCyproteroneMitoxantroneDrug Administration ScheduleAntibodies, Monoclonal, Murine-DerivedDrug Therapy, CombinationAnti-Inflammatory AgentsNeoplasms, Hormone-DependentTestisAnimal WelfareBleomycinTime FactorsMethotrexateGonadotropin-Releasing HormoneTosyl CompoundsEpididymisColor TherapyHydrocortisoneRemission InductionAntineoplastic Agents, HormonalChlorambucilLymphoma, Non-HodgkinButorphanolAndrostenolsProstate-Specific AntigenEstradiolRandom AllocationCyclosporineHaptoglobinsOrgan SizeHodgkin DiseaseLymphoma, Large B-Cell, DiffuseCombined Modality TherapyDrug ImplantsAnesthesia, LocalMycophenolic AcidKetoprofenZeranolFollow-Up StudiesLuteinizing HormoneAndrogen Receptor AntagonistsXylazineVinblastineGonadal Steroid HormonesHornsOvariectomyAsparaginaseAdrenal Cortex HormonesSurvival AnalysisAdministration, OralThalidomideMultiple MyelomaDisease-Free SurvivalAnilidesKidney TransplantationSexual MaturationEtoposideLeuprolideTestosterone PropionateScrotum5-alpha Reductase InhibitorsTaxoidsTrematodaGraft RejectionAzasteroidsRecurrenceTacrolimusMethylprednisoloneSex CharacteristicsSurvival RateDose-Response Relationship, DrugHarderian GlandDisease ProgressionAnesthesia, CaudalFinasterideNephrotic Syndrome